4 news items
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
MIRM
6 Jun 24
, Bergamo, Italy
This analysis aimed to assess correlations between serum bile acid (sBA) improvements
Mirum Pharmaceuticals Gets Positive CHMP Opinion For LIVMARLI Oral Solution For The Treatment Of PFIC In Patients 3-Months Or Older
MIRM
31 May 24
between LIVMARLI vs. placebo across all PFIC types studied.CHMP assessment concluded that LIVMARLI in PFIC brings significant clinical benefit
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
MIRM
31 May 24
studied.
CHMP assessment concluded that LIVMARLI in PFIC brings significant clinical benefit over
Analyst Ratings For Mirum Pharmaceuticals
MIRM
9 May 24
0
Analysts provide deeper insights through their assessments of 12-month price targets
- Prev
- 1
- Next